METHOD & SOURCES
How this CRO comparison uses sources and dates
The original comparison has 39 vendor statements across 16 CROs. This review adds 6 source-linked statements covering therapeutic scope, ICON general operations and Medpace’s team-continuity claim. See the new source records. Every claim is vendor-authored; none demonstrates study-specific outcomes, ClinicalTrials.gov trial counts, named team capacity, or trial pricing. Shared limits apply across every page rather than being repeated in every comparison cell.
Why some cells are marked unknown
When a reviewed CRO page covers only one offering (for example, IQVIA’s Phase IIb/III service page or ICON’s Accellacare in-home page) or summarizes only high-level corporate positioning (for example, Premier Research’s homepage), missing fields are marked as not stated or not detailed on the reviewed page rather than inferred from general reputation or third-party directories.
Sources, read dates, and exact hashes
- iqvia · phase_evidence: https://www.iqvia.com/solutions/research-and-development/phase-iibiii-trials · read 2026-11-13 · snapshot SHA-256
b61379ce9a54bc4103f549577cf52ecf067c75eae6fbbd4a1c95eef313101e41 · fact SHA-256 ac02829ebc869a23f126b42d7489d4af5977d860c6f80b0361999e89438e848a - icon · phase_evidence: https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services · read 2026-11-13 · snapshot SHA-256
6e3784f42e963bc0836991255ed9cbaeb3b251a8e083a1bedcfbbd8d43e55653 · fact SHA-256 9f88b737206de9ad3842208bb1ff7e487424425ece9480768b1327920d88385a - medpace · phase_evidence: https://www.medpace.com/ · read 2026-11-13 · snapshot SHA-256
2848676ea722260c95320de3049519181981762a2a926cdfc7838514b1b02086 · fact SHA-256 ad3d4d09bb9e81623ee59c07312c2d8ab2e04ad94ca0969882a88bff4ca82da6 - medpace · service_scope: https://www.medpace.com/ · read 2026-11-13 · snapshot SHA-256
2848676ea722260c95320de3049519181981762a2a926cdfc7838514b1b02086 · fact SHA-256 869cf9d66eb887457e6b3573c0a11bf0d1b552c06ccec87443fc506905c427a8 - parexel · phase_evidence: https://www.parexel.com/solutions/integrated-clinical-development · read 2026-11-13 · snapshot SHA-256
d205de6b02876a32ccb4e249cc5b4d205aa20bfee202791ee1286eff9207fc4a · fact SHA-256 be913ec49bafed9006aaebe77cf2b76252356213e908fe70f2931a5366348772 - parexel · therapeutic_area_evidence: https://www.parexel.com/solutions/integrated-clinical-development · read 2026-11-13 · snapshot SHA-256
d205de6b02876a32ccb4e249cc5b4d205aa20bfee202791ee1286eff9207fc4a · fact SHA-256 24e7f0e3633aa51087bdb34e7ad63c361085e65675e2a5458411ccba2c656792 - parexel · service_scope: https://www.parexel.com/solutions/integrated-clinical-development · read 2026-11-13 · snapshot SHA-256
d205de6b02876a32ccb4e249cc5b4d205aa20bfee202791ee1286eff9207fc4a · fact SHA-256 6694bb78c1bd76fede9bd2916ad271734e891cbc904be2cc328bc533d32ebfd0 - syneos-health · phase_evidence: https://www.syneoshealth.com/solutions/clinical-development · read 2026-11-13 · snapshot SHA-256
11182c52c1042789f556a5dd6aa9d0cfb5af6a0f04c24bcab14a32001ee03f44 · fact SHA-256 a6ac3e52085e3006962c8fad7ce6281f74ad78f77c0ba6e3fd9c31696bdd17ac - syneos-health · therapeutic_area_evidence: https://www.syneoshealth.com/solutions/clinical-development · read 2026-11-13 · snapshot SHA-256
11182c52c1042789f556a5dd6aa9d0cfb5af6a0f04c24bcab14a32001ee03f44 · fact SHA-256 a2e524cdefa7d684ba0b9a03cabb0aec77403794f61dc5aa3bb856e696f8703a - syneos-health · service_scope: https://www.syneoshealth.com/solutions/clinical-development · read 2026-11-13 · snapshot SHA-256
11182c52c1042789f556a5dd6aa9d0cfb5af6a0f04c24bcab14a32001ee03f44 · fact SHA-256 7f754a321ba9e57acd47e200f1515444b32b1d00b79f4e90436394fd0244029e - fortrea · service_scope: https://www.fortrea.com/clinical-solutions/clinical-development · read 2026-11-13 · snapshot SHA-256
fff5db9129654d7b5bd4da84eb6aaf77f10ebc3f83cd77187d58a116b01156ec · fact SHA-256 8ec3754ae0575be8edbd2983b1599d01eb9f215576b4818f6cd18bfaa27a042c - thermo-fisher-ppd · phase_evidence: https://www.thermofisher.com/us/en/home/brands/ppd.html · read 2026-11-13 · snapshot SHA-256
9465c2af1bf8726cbea43b8fef79f68cd47f9b88f40669aec4ac570e8618e736 · fact SHA-256 8c73771335cd859b164483005a232151fe174d13bb0687df7093e70cfd5efefe - thermo-fisher-ppd · service_scope: https://www.thermofisher.com/us/en/home/brands/ppd.html · read 2026-11-13 · snapshot SHA-256
9465c2af1bf8726cbea43b8fef79f68cd47f9b88f40669aec4ac570e8618e736 · fact SHA-256 37deb0910b113af79b06a855765d93b35ca2f26be0348e246d17744be1d6be04 - labcorp · service_scope: https://www.labcorp.com/biopharma · read 2026-11-13 · snapshot SHA-256
aa2be5d02b402ecc05be9e30f4a3d562111f600a616474f4550266272f726730 · fact SHA-256 6be47bfe3eaf71a49af264d3bfb7df851339d57b866130ac4a93b84a7d6bc13b - worldwide-clinical-trials · phase_evidence: https://www.worldwide.com/solutions/ · read 2026-11-13 · snapshot SHA-256
8479d95654b4b97c08ddb185a4d9aca5c336008d766c9418682d2f5cef4c229f · fact SHA-256 a293ccde06ab5e074d3ff022e795b10540df7b674ee1d5708acef1effe19d6a1 - worldwide-clinical-trials · service_scope: https://www.worldwide.com/solutions/ · read 2026-11-13 · snapshot SHA-256
8479d95654b4b97c08ddb185a4d9aca5c336008d766c9418682d2f5cef4c229f · fact SHA-256 998e9c4c227dc8b8ca1041092ab813648217ad0d91da6460e7ca4446b66c0390 - precision-for-medicine · phase_evidence: https://www.precisionformedicine.com/clinical-trial-services/cro-services · read 2026-11-13 · snapshot SHA-256
81c5ea37a87fa76851594b79403ac470060e638326ca61ae9463a21e73b2c234 · fact SHA-256 a7c75471e4fa7db6069d895282c24563106c6f0c4693a45f0be289bcedef3203 - precision-for-medicine · therapeutic_area_evidence: https://www.precisionformedicine.com/clinical-trial-services/cro-services · read 2026-11-13 · snapshot SHA-256
81c5ea37a87fa76851594b79403ac470060e638326ca61ae9463a21e73b2c234 · fact SHA-256 a17d3b2573fce05370be15d53b4e2905b52f553c443e7e66338226ffe7a86f00 - precision-for-medicine · service_scope: https://www.precisionformedicine.com/clinical-trial-services/cro-services · read 2026-11-13 · snapshot SHA-256
81c5ea37a87fa76851594b79403ac470060e638326ca61ae9463a21e73b2c234 · fact SHA-256 ea446d6107f6d2205ca8eb547be172222e2094f49c2659ef0f1211ab969179fb - veristat · phase_evidence: https://www.veristat.com/what-we-do · read 2026-11-13 · snapshot SHA-256
7b8a1089d0495ac90f333249fd19fa07d00fd91e03c79f54c2b56fd6be7936e8 · fact SHA-256 98636789ef2709a9a60c179173c573cd04c13088cb28171df226486dd390a16c - veristat · therapeutic_area_evidence: https://www.veristat.com/what-we-do · read 2026-11-13 · snapshot SHA-256
7b8a1089d0495ac90f333249fd19fa07d00fd91e03c79f54c2b56fd6be7936e8 · fact SHA-256 f9075f7d085dd976335d5bf67204eb1002663c56fe2386b00f911664b41e2629 - veristat · service_scope: https://www.veristat.com/what-we-do · read 2026-11-13 · snapshot SHA-256
7b8a1089d0495ac90f333249fd19fa07d00fd91e03c79f54c2b56fd6be7936e8 · fact SHA-256 b539261e2d1b85dd433297caf2040927f924567bed9a93c301f2313c1b95e262 - premier-research · service_scope: https://premier-research.com/ · read 2026-11-13 · snapshot SHA-256
ba152127c41084e80db2d9470a5ca4d152b3ca54ca7f4a871d5d50834af780bf · fact SHA-256 3e86e9ba13f64cb234e2edadce4769d6336abfe9a215ceea35ea2292be4bea7c - indero · phase_evidence: https://inderocro.com/ · read 2026-11-13 · snapshot SHA-256
311cc285fdb2bd1ba93ae6a2ad936f1e9cde09ddd25e168a48c725e0f127e7ba · fact SHA-256 a1be3d4df20ae699a7dbe5d12c6ebf1b87aec1ab99fb77d068e7b88b4a032bdb - indero · therapeutic_area_evidence: https://inderocro.com/ · read 2026-11-13 · snapshot SHA-256
311cc285fdb2bd1ba93ae6a2ad936f1e9cde09ddd25e168a48c725e0f127e7ba · fact SHA-256 69d62573837d1013d446f759e32b1a05b83f8b1aa4383adc5b5d2a619ce81777 - indero · service_scope: https://inderocro.com/ · read 2026-11-13 · snapshot SHA-256
311cc285fdb2bd1ba93ae6a2ad936f1e9cde09ddd25e168a48c725e0f127e7ba · fact SHA-256 864e5849d091be70c40bbe9ecebb136a7caafebe4446e598566c5a93356db8a6 - kapadi · therapeutic_area_evidence: https://kapadi.com/ · read 2026-11-13 · snapshot SHA-256
99bc19dc9b3e8362f0f53135ebceceeb53663a67927ee32fdd11613aa18a6434 · fact SHA-256 b35b11dcff32d34207741c9d245dbedf2507c8bfc096d25dda19f032a74bd4b9 - kapadi · service_scope: https://kapadi.com/ · read 2026-11-13 · snapshot SHA-256
99bc19dc9b3e8362f0f53135ebceceeb53663a67927ee32fdd11613aa18a6434 · fact SHA-256 ff57bd8c5bbf60eb5b8794d48a621f1f090df3227601e0a272ae932e24d58b24 - pharpoint · phase_evidence: https://pharpoint.com/full-service-cro/ · read 2026-11-13 · snapshot SHA-256
174075bad5c9bdcbce09cd4ad978e29aeea09b6e3a811934c4b224b0ad87ae91 · fact SHA-256 456838413e63aa815abe3a40b54414f177935751741a9ee55aed12b81fd3e0ed - pharpoint · service_scope: https://pharpoint.com/full-service-cro/ · read 2026-11-13 · snapshot SHA-256
174075bad5c9bdcbce09cd4ad978e29aeea09b6e3a811934c4b224b0ad87ae91 · fact SHA-256 5ccc5c18684b6aedd5d2d81c0cbad7da445e3be975d3603074505ac6c8e2f8bd - proxima-cro · service_scope: https://www.proximacro.com/ · read 2026-11-13 · snapshot SHA-256
417c8e705c5a4d180bac90357fea1edf5f556581db2ba7f8138bc37895331783 · fact SHA-256 f66cb374e93dd8ace8745345e975662c36bf79c79f3df2e0d3c9f5ba8fd09f20
Change review guard
The build compares current accepted fact and source-snapshot hashes against a retained baseline (accepted-evidence.json) before writing pages or dependency bindings. A changed or missing accepted input writes a review queue and stops the build while preserving the accepted baseline until review. No automatic scheduler is installed.
← Back to CRO overview
Sources for the added answers
Download the added facts (JSON)
IQVIA · Therapeutic and Specialty Expertise
Open primary source ↗
Read 2026-11-14T03:56:44.432492+00:00 · Vendor documentation · Explicit FAQ list read beyond navigation; broad company scope, not study-specific evidence.
Saved capture SHA-256: 62f9cd25b56159fef22b58b8cab99a98e7be9feca4eb062a4c1112a876a60aac
Passages used
- therapeutic area evidence: FAQ L643–L645
ICON · Clinical and Scientific Operations
Open primary source ↗
Read 2026-11-14T03:56:44.426308+00:00 · Vendor documentation · General Phase 2–3 clinical operations, separate from Accellacare in-home offering.
Saved capture SHA-256: c0aaad4b280ab5515db09d6167ce8ea1e29a85736cac7f594be5341d171b796b
Passages used
- phase evidence: L1–L3
- therapeutic area evidence: L37–L40
- service scope: L37–L40
Medpace · About Medpace
Open primary source ↗
Read 2026-11-14T03:56:44.432492+00:00 · Vendor documentation · Explicit therapeutic FAQ and team-continuity claim; no independently verified team allocation or turnover comparison.
Saved capture SHA-256: 648e644e0357c50d0d35f6a7601a7c83178d504373d5b6877ac610e9859b1316
Passages used
- therapeutic area evidence: FAQ L202–L229
- team continuity claim: L234–L236